Pharmaceutical Technology

JULY 1, 2025

The US Food and Drug Administration (FDA) has approved Takeda’s new immunoglobulin (IG) therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat primary immunodeficiency (PI) in individuals aged two years and above. Credit: HenadziPechan/Shutterstock. Give your business an edge with our leading industry insights.

FDA 52

FDA Packaging Communication Hospitals 52

Pharmaceutical Technology

JUNE 20, 2025

Find out more This treatment involves obtaining immune cells from patients, modifying them in a laboratory setting then reintroducing them into patients’ bodies to destroy cancerous cells. We may still continue to send you service-related and other non-promotional communications. Don’t let policy changes catch you off guard.

Hospitals 52

Hospitals Communication Immunization Packaging 52

Pharmaceutical Technology

JULY 1, 2025

A preliminary look at the data from Capstan has revealed strong B-cell depletion – the aim of the treatment is to achieve an ‘immune reset’ by repopulation of healthy B cells. We may still continue to send you service-related and other non-promotional communications. higher at $185.62 on 30 June, the day the announcement was made.

Packaging 52

Packaging Communication Hospitals FDA 52

Pharmaceutical Technology

JULY 3, 2025

It comes with one for cytokine release syndrome (CRS) and neurologic toxicity – including immune effector cell-associated neurotoxicity syndrome – in addition to warnings and precautions for infections, neutropenia, hepatotoxicity and embryo-foetal toxicity. Give your business an edge with our leading industry insights.

FDA 52

FDA Packaging Communication Hospitals 52

Pharmaceutical Technology

JUNE 11, 2025

CD4+T-cells and lymphocytes are both crucial elements of the immune system. Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications.

HIV Treatment and Prevention Agents 52

HIV Treatment and Prevention Agents FDA Communication Hospitals 52

Pharmaceutical Technology

JULY 14, 2025

A single dose of the vaccine in adults aged 18-49 at increased risk of RSV-LRTD elicited robust immune responses that were non-inferior to those observed in adults aged 60 and above. That is instead recommended by the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP).

Labelling 52

Labelling Vaccines FDA Packaging 52

Pharmaceutical Technology

JULY 11, 2025

Its design minimises interaction with Fc-gamma (Fcγ) receptors on macrophages, enhancing the ability of the body’s immune cells to recognise and combat tumours. Give your business an edge with our leading industry insights. Thank you for subscribing View all newsletters from across the GlobalData Media network.

Packaging 52

Packaging Hospitals Communication Labelling 52

Pharmaceutical Technology

JULY 15, 2025

LaNova’s drug development focuses on tumour immunity and the tumour microenvironment. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

Packaging 75

Packaging Communication Hospitals Vaccines 75

Pharmaceutical Technology

JUNE 16, 2025

Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. Can pharma tariffs “Make America Manufacture Again”? Based on these trial results, Keytruda as part of this regimen shows potential to change long-standing standards of care for treating certain patients with locally advanced HNSCC.”

FDA 52

FDA Research Laboratories Communication Hospitals 52

Pharmaceutical Technology

JULY 4, 2025

Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Nominate Now Share Copy Link Share on X Share on Linkedin Share on Facebook Go deeper with GlobalData Reports LOA and PTSR Model - Briquilimab in Severe Combined Immune Deficien. Find out more Sign up for our daily news round-up!

Hospitals 52

Hospitals Packaging Communication Immunization 52

Pharmaceutical Technology

JULY 15, 2025

LEO’s new asset is a monoclonal antibody that blocks the activation of the interleukin-36 (IL-36) receptor – a key signalling pathway in the immune system implicated in the pathogenesis of several autoinflammatory diseases. It has also been approved in expanded indications in GPP in certain territories.

Packaging 52

Packaging Communication Hospitals Vaccines 52

Pharmaceutical Technology

JUNE 13, 2025

This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 52

Vaccines FDA Labelling Communication 52

Pharmaceutical Technology

JUNE 10, 2025

The US department of Health and Human Services (HHS) has culled the 17 Biden-appointed members on the Advisory Committee for Immunization Practices (ACIP) at the Centers for Disease Control and Prevention (CDC) in a move observers warn is liable to further fuel the spread of vaccine-preventable illnesses. lev radin via Shutterstock.

Vaccines 52

Vaccines FDA Immunization Communication 52

Pharmaceutical Technology

JUNE 12, 2025

By GlobalData Learn more about Strategic Intelligence By covering a wide range of targets on malignant B cells, the therapy aims to enhance safety and efficacy while minimising the potential of tumour cells for developing immune-resistance mechanisms such as antigen escape. Can pharma tariffs “Make America Manufacture Again”?

Communication 52

Communication Hospitals Packaging Insurance 52

Pharmaceutical Technology

JUNE 25, 2025

In a controversial move on 9 June 2025, US Secretary of Health and Human Services Robert F Kennedy Jr dismissed all 17 members of the Centers for Disease Control and Prevention (CDC) Advisory Committee for Immunization Practices (ACIP) that advises the federal government on vaccine safety. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 52

Vaccines Packaging Hospitals Communication 52

Pharmaceutical Technology

JUNE 25, 2025

RFK Jr has flip-flopped between endorsing and shunning the MMR vaccine , a shot that is proven to provide strong immunity against the disease. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

Vaccines 116

Vaccines Hospitals Packaging Communication 116

Pharmaceutical Technology

JUNE 16, 2025

A low incidence of immune effector cell-associated neurotoxicity syndrome was reported during the step-up dosing phase and the target dose phase. Can pharma tariffs “Make America Manufacture Again”? Two patients experienced dose-limiting toxicities and continued to receive the targeted dose.

Labelling 52

Labelling Communication Hospitals Vaccines 52

pharmaphorum

JULY 9, 2021

That’s according to Dr Gareth Parkes – a full-time gastroenterologist who co-founded Ampersand Health, which develops digital therapeutics for inflammatory bowel disease (IBD) and other immune mediated inflammatory diseases (IMIDs). Digital therapeutics in practice. About the interviewees.

Hospitals 69

Hospitals Communication Immunization Pharmaceutical Companies 69

Pharmaceutical Technology

JUNE 12, 2025

Amongst the new members on the CDC’s Advisory Committee for Immunization Practices (ACIP) are well-known vaccine sceptics and individuals who were critical of both the Covid-19 vaccines and related countermeasures such as lockdowns. Can pharma tariffs “Make America Manufacture Again”?

Vaccines 52

Vaccines Hospitals Communication Immunization 52

ISPE

OCTOBER 27, 2022

This can be challenging for many reasons: it can be difficult to estimate the size and number of polynucleotides to transfer, the efficiency of the vector in the particular cells addressed, the scale of production required, and whether a patient’s immune system will respond to vector particles as a microorganism. Accessed 11 August 2022.

Packaging 52

Packaging Communication Immunization Vaccines 52

Pharmaceutical Technology

JULY 8, 2025

The medical groups also pointed to sweeping changes made on the CDC’s Advisory Committee for Immunization Practices (ACIP), the committee responsible for reviewing vaccine data and issuing official government recommendations on immunisations. There have been three confirmed deaths from the disease, all in unvaccinated children.

Vaccines 75

Vaccines Packaging Communication Hospitals 75

pharmaphorum

AUGUST 13, 2020

New York Magazine , the New York Times and The Economist amongst many other news organisations knocked down their paywalls for COVID-19-related coverage to keep readers informed in a rapidly changing and often confusing environment. In Britain, the venerable BBC launched BBC Bitesize to help parents home-school children.

Health and Personal Care Stores 112

Health and Personal Care Stores Vaccines Communication Pharmaceutical Companies 112